Celldex Therapeutics reported $367.98M in Current Assets for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Current Assets Change
Agenus AGEN:US $ 288.93M 1.55M
Amgen AMGN:US $ 19322M 802M
Applied Genetic Technologies AGTC:US $ 49.56M 20.97M
Aptinyx Inc APTX:US $ 92.14M 14.39M
Biocept BIOC:US $ 47.58M 1.89M
Bristol Myers Squibb BMY:US $ 30186M 65M
Celldex Therapeutics CLDX:US $ 367.98M 22.72M
Cytrx CYTR:US 6.18M 2.1M
Glaxosmithkline GSK:US $ 54188M 25200M
Immunogen IMGN:US $ 373.87M 82.84M
Merrimack Pharmaceuticals MACK:US $ 14.04M 569K
Nektar Therapeutics NKTR:US $ 665.54M 67.92M
Newlink Genetics NLNK:US 84.99M 7.66M
Northwest Biotherapeutics NWBO:US 7.18M 2.09M
Rigel Pharmaceuticals RIGL:US $ 120.52M 18.42M
Seattle Genetics SGEN:US $ 2778.66M 7.4M